Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

Clinicaltrial registered26 Oct 2026

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

26 Oct 2026: Trial registered · Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
26 Oct 2026
Title
Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Conditions
Atopic Dermatitis (AD)
Phase
Phase 2
Study Type
Interventional
Status
Recruiting
Countries
China
Country
China
Reference
NCT07895615
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.